InflaRx NV opened higher at $1.21, compared with its previous close of $1.18. In the last trading session, the stock traded between $1.15 and $1.25. It showed an upward intraday trend.
An investment of $100 made 5 years ago in InflaRx NV is now worth
$ 25.25
Resulting in a loss of
$ 74.75 (74.75%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
+$0.06 (+5.08%)
Day High
$1.25
Day Low
$1.15
Day Open
$1.21
Prev Close
$1.18
Volume
7,24,511
1W Return
-15.59%
1M Return
-21.87%
3M Return
-38.15%
6M Return
-50.40%
1Y Return
-24.85%
Market Cap ($ Mn)
183
PE Ratio
-
PB Ratio
1.96
PEG Ratio
-
ROE
-82.71%
ROCE
-85.22%
EPS (TTM)
$-0.02
1 Week
-15.59%
1 Month
-21.87%
3 Months
-38.15%
6 Months
-50.40%
9 Months
45.73%
InflaRx publishes Phase 1 data for oral C5aR1 inhibitor izicopan
Peer-reviewed publication confirms Phase 1 data for oral C5aR1 inhibitor izicopan. Study involved 86 healthy participants in randomized, placebo-controlled design. Results showed rapid, sustained inhibition of C5a/C5aR1 signaling. Drug was well tolerated across all single and multiple doses evaluated. Findings support progression to Phase 2 development in immune-inflammatory diseases.
6 days agoInflaRx Q3 loss narrows to $0.02 per share, beats estimates
InflaRx reported a Q3 loss of $0.02 per share. The result beat the analyst consensus estimate of $0.07 by 71.43%. Quarterly losses narrowed 90.48% from $0.21 in the prior year.
9 days agoInflaRx presents pre-clinical data on izicopan's renal protection
InflaRx presented pre-clinical data showing izicopan significantly reduced renal injury markers in hamster models. A single 100 mg/kg dose in IRI models lowered creatinine and BUN with p < 0.001 significance. Structural modeling indicates izicopan has lower CYP3A4/5 interaction risk than avacopan. The company plans to advance izicopan in ANCA-associated vasculitis and other kidney diseases.
21 days agoInflaRx to present izicopan pre-clinical data at Kidney Week 2026
InflaRx selected for late-breaking poster at ASK Kidney Week 2026 in Denver. Izicopan to be presented as promising therapy for kidney disease models. Pre-clinical data shows ≥90% blockade of C5a-induced neutrophil activation. Oral C5aR1 antagonist avoids CYP3A4 inhibition seen in other inhibitors.
1mo agoInflaRx to Host Virtual Capital Markets Day on November 3
InflaRx will host a virtual Capital Markets Event on November 3, 2026, from 8:00 am EST to 9:00 am EST. The event focuses on izicopan’s potential to improve standard of care in ANCA-associated vasculitis. Featured speakers include Peter A. Merkel from University of Pennsylvania and Jörg Köhl from University of Lübeck. Izicopan demonstrated ≥90% blockade of C5a-induced neutrophil activation in first-in-human studies.
1mo agoInflaRx to present at Cantor, Wainwright investor conferences in September
InflaRx N.V. (NASDAQ: IFRX) announced its participation in two September 2026 investor conferences in New York. The company will hold a fireside chat at the Cantor Global Healthcare Conference on September 9 and a presentation at the H.C. Wainwright conference on September 14. These events will highlight progress on its lead programs, including izicopan and vilobelimab.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in InflaRx NV is now worth
$ 25.25
Resulting in a loss of
$ 74.75 (74.75%)
Note: Past profits do not guarantee future returns.
